Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 1:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,310 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Head & Neck Cancer Clear all

Conditions: Gastrointestinal Disease, Esophageal Cancer, Lung Cancer
Interventions: Breathing Test, Respiratory Symptoms Questionnaire, Pet Scan; Procedure · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Uterine Cancer, Rectal Cancer, Colon Cancer, Breast Cancer, Lung Cancer, Sarcoma, Cervix Cancer, Head and Neck Cancer, Anal Cancer, Liver Cancer, Gastric Cancer, Bladder Cancer
Interventions: HyperSight cone beam computed tomography (CBCT) scan, ETHOS 2.0; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Colorectal Cancer, Head and Neck Cancer
Interventions: Urelumab, Cetuximab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 7
States / cities: Stanford, California • Chicago, Illinois • Baltimore, Maryland + 4 more

Conditions: Papillomavirus Infections, Oropharyngeal Neoplasms
Interventions: E7 TCR; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Solid Tumor, NSCLC, Colorectal Cancer, Head and Neck Cancer, Cholangiocarcinoma
Interventions: [225Ac]Ac-FL-261; Drug
Lead sponsor: Full-Life Technologies UK Limited; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Interventions: docetaxel, oxaliplatin, vandetanib, placebo; Drug · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Esophageal, Gastrooesophageal Cancer, Gastric Cancer
Interventions: jevtana; Drug
Lead sponsor: howard safran; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Pawtucket, Rhode Island • Providence, Rhode Island

Conditions: Advanced Solid Tumors
Interventions: ALKS 4230, ALKS 4230 + pembrolizumab; Drug
Lead sponsor: Mural Oncology, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 12
States / cities: Denver, Colorado • Port Saint Lucie, Florida • Tampa, Florida + 9 more

Conditions: Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms
Interventions: KFA115, pembrolizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more

Conditions: Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions: PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo); Drug · Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more

Conditions: Head and Neck Neoplasms, Hearing Disorder, Hyperlipidemia
Interventions: Not listed
Lead sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD); NIH
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Stage I Oral Cavity Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma
Interventions: HPPH, Laboratory Biomarker Analysis, Photodynamic Therapy, Quality-of-Life Assessment, Therapeutic Conventional Surgery; Drug · Other · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Buffalo, New York • Rochester, New York

Conditions: Oropharyngeal Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions: Standard Radiation Treatment, Dose-Deescalated Treatment, Cisplatinum; Radiation · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Head and Neck Carcinoma
Interventions: Not listed
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Head and Neck Cancer
Interventions: Magnetic Resonance Imaging (MRI), Ferumoxytol; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Cancer
Interventions: Pebrolizumab + QUADSHOT Radiotherapy; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Cancer of Head and Neck
Interventions: Erbitux, Paclitaxel & Carboplatin, Radiation; Drug · Radiation
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
Interventions: disitamab vedotin; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 75
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 36 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Tirapazamine, Cisplatin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: Cesium 131; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years to 90 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Oral Mucositis
Interventions: ALD518, 0.9% saline; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Clearwater, Florida • Boston, Massachusetts • Detroit, Michigan + 10 more

Conditions: Esophageal Adenocarcinoma
Interventions: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin); Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Head Neck Cancer
Interventions: Medpulser Electroporation with Bleomycin, Surgical Excision; Combination Product · Procedure
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: San Diego, California

Conditions: Head and Neck Cancer, Thyroid Cancer
Interventions: MRI examinations; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

PMRR-NO: Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer

A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer

SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET

Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction

Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen

A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

Hearing Loss and the Effects of Statin Drugs in People With Head and Neck Squamous Cell Carcinoma Treated With Cisplatin Chemoradiation

Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer

Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma

Effects of Human Papillomavirus Diagnosis on Relationships of Patients With Head and Neck Cancer

Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI

"QUAD SHOT" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer

Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

TRACE: Tirapazamine-Radiation And Cisplatin Evaluation

Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck Cancer

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma

Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma

New MRI Biomarkers in Head and Neck Cancers